TY - JOUR
T1 - Guidelines for Sexual Health Care for Prostate Cancer Patients
T2 - Recommendations of an International Panel
AU - Wittmann, Daniela
AU - Mehta, Akanksha
AU - McCaughan, Eilis
AU - Faraday, Martha
AU - Duby, Ashley
AU - Matthew, Andrew
AU - Incrocci, Luca
AU - Burnett, Arthur
AU - Nelson, Christian J.
AU - Elliott, Stacy
AU - Koontz, Bridget F.
AU - Bober, Sharon L.
AU - McLeod, Deborah
AU - Capogrosso, Paolo
AU - Yap, Tet
AU - Higano, Celestia
AU - Loeb, Stacy
AU - Capellari, Emily
AU - Glodé, Michael
AU - Goltz, Heather
AU - Howell, Doug
AU - Kirby, Michael
AU - Bennett, Nelson
AU - Trost, Landon
AU - Odiyo Ouma, Phillip
AU - Wang, Run
AU - Salter, Carolyn
AU - Skolarus, Ted A.
AU - McPhail, John
AU - McPhail, Susan
AU - Brandon, Jan
AU - Northouse, Laurel L.
AU - Paich, Kellie
AU - Pollack, Craig E.
AU - Shifferd, Jen
AU - Erickson, Kim
AU - Mulhall, John P.
N1 - Funding Information:
Stacy Loeb is supported by Department of Defense Idea Development Award W81XWH2010380.
Funding Information:
Funding: This work was supported and funded by Movember. Conflict of Interest: Daniela Wittmann is routinely supported by the Department of Urology of the University of Michigan to attend annual meetings of the American Urological Association and the Sexual Medicine Society of North America, is a past Member of the Board of Directors of the Sexual Medicine Society of North America, and is an associate editor of the Journal of Sexual Medicine. Sharon L. Bober reports receiving honoraria from UpToDate and Johns Hopkins University and being chair for the Scientific Network on Female Sexual Health and Cancer. Stacy Loeb is supported by Department of Defense Idea Development Award W81XWH2010380. Ted A. Skolarus reports UpToDate royalties for authorship on a prostate cancer survivorship topic; he also reports grants from the National Cancer Institute (R37CA222885 and R01CA242559). Bridget F. Koontz is a consultant for Rythera Therapeutics; reports research funding from Janssen Scientific Affairs, Merck Pharmaceuticals, and Blue Earth Diagnostics; receives royalties from Demos Publishing; is a symposium steering committee member for the American Society of Clinical Oncology; is a committee member for the American Association of Physicists in Medicine, the National Cancer Institute, and NRG; and is on advisory boards for Bayer, Blue Earth Diagnostics, and Myovant. L. Michael Glodé reports grants or contracts from the National Institutes of Health and the State of Colorado; consultancy for Janssen, Exelixis, Bayer, and Seattle Genetics; participation on boards for Janssen and Exelixis; multiple patents (none related to the topic of this article); committee membership for Movember; and stock or stock options in Aurora Oncology. John P. Mulhall is an Editor in Chief of the Journal of Sexual Medicine; advisor to Vault Health and reports stock or stock options in Vault Health, has received payment for expert testimony, and has received support for attending meetings and/or travel from Memorial Sloan Kettering. Laurel L. Northouse reports personal stock in Microsoft and Stryker and consulting fees for the Dyadic Interventions for people with Advanced cancer and their Informal Caregivers study. Kellie Paich is an employee of Movember. Christian J. Nelson reports a grant from the National Institutes of Health (R01 CA190636). Craig E. Pollack reports stock ownership in Gilead Pharmaceuticals and is working on a temporary assignment at the Department of Housing and Urban Development (HUD); this report does not represent the views of HUD. Nelson Bennett is a speker for Endo Pharmaceutical Company and Coloplast, he has a training grant from Coloplast. Michael Kirby is a speaker for the following pharmaceutical companies – Lilly, Astra Zeneca, Glaxo-Smith-Kline. Run Wang is a speaker for Boston Scientific, Teleflex and Coloplast. Arthur Burnett receives research grant support from: Endo Pharmaceutical, Boston Scientific, and the National Institutes of Health. He is a consultant and advisor to Boston Scientific, Coloplast, Reflexonic, Astellas, Novartis, Futura Medical, Comphya SA, and Myriad Genetics; he is a patent holder for MHN Biotech; he is a member of the following Boards: Urology Care Foundation, The American Urological Association PAC, and Mentoring Mae teens in the Hood. He is a member of the editorial boards of Urology Practice, Andrology, Canadian Journal of Urology, International Urology and Nephrology, Urology Time; he is on the board of UroMissionsWorks Inc (Non-profit). Ashley Duby is the owner of Midwest Premier Business Solutions, LLC and is contracted with Movember to provide assistance with project management. The other authors made no disclosures.
Funding Information:
Christian J. Nelson reports a grant from the National Institutes of Health (R01 CA190636).
Funding Information:
Bridget F. Koontz is a consultant for Rythera Therapeutics; reports research funding from Janssen Scientific Affairs, Merck Pharmaceuticals, and Blue Earth Diagnostics; receives royalties from Demos Publishing; is a symposium steering committee member for the American Society of Clinical Oncology; is a committee member for the American Association of Physicists in Medicine, the National Cancer Institute, and NRG; and is on advisory boards for Bayer, Blue Earth Diagnostics, and Myovant. L.
Publisher Copyright:
© 2022 International Society for Sexual Medicine
PY - 2022/11
Y1 - 2022/11
N2 - Background: Patients with prostate cancer suffer significant sexual dysfunction after treatment which negatively affects them and their partners psychologically, and strain their relationships. Aim: We convened an international panel with the aim of developing guidelines that will inform clinicians, patients and partners about the impact of prostate cancer therapies (PCT) on patients’ and partners’ sexual health, their relationships, and about biopsychosocial rehabilitation in prostate cancer (PC) survivorship. Methods: The guidelines panel included international expert researchers and clinicians, and a guideline methodologist. A systematic review of the literature, using the Ovid MEDLINE, Scopus, CINAHL, PsychINFO, LGBT Life, and Embase databases was conducted (1995–2022) according to the Cochrane Handbook for Systematic Reviews of Interventions. Study selection was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Each statement was assigned an evidence strength (A-C) and a recommendation level (strong, moderate, conditional) based on benefit/risk assessment. Data synthesis included meta-analyses of studies deemed of sufficient quality (3), using A Measurement Tool to Assess Systematic Reviews (AMSTAR). Outcomes: Guidelines for sexual health care for patients with prostate cancer were developed, based on available evidence and the expertise of the international panel. Results: The guidelines account for patients’ cultural, ethnic, and racial diversity. They attend to the unique needs of individuals with diverse sexual orientations and gender identities. The guidelines are based on literature review, a theoretical model of sexual recovery after PCT, and 6 principles that promote clinician-initiated discussion of realistic expectations of sexual outcomes and mitigation of sexual side-effects through biopsychosocial rehabilitation. Forty-seven statements address the psychosexual, relationship, and functional domains in addition to statements on lifestyle modification, assessment, provider education, and systemic challenges to providing sexual health care in PC survivorship. Clinical Implications: The guidelines provide clinicians with a comprehensive approach to sexual health care for patients with prostate cancer. Strengths & Limitations: The strength of the study is the comprehensive evaluation of existing evidence on sexual dysfunction and rehabilitation in prostate cancer that can, along with available expert knowledge, best undergird clinical practice. Limitation is the variation in the evidence supporting interventions and the lack of research on issues facing patients with prostate cancer in low and middle-income countries. Conclusion: The guidelines document the distressing sexual sequelae of PCT, provide evidence-based recommendations for sexual rehabilitation and outline areas for future research. Wittmann D, Mehta A, McCaughan E, et al. Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel. J Sex Med 2022;19:1655–1669.
AB - Background: Patients with prostate cancer suffer significant sexual dysfunction after treatment which negatively affects them and their partners psychologically, and strain their relationships. Aim: We convened an international panel with the aim of developing guidelines that will inform clinicians, patients and partners about the impact of prostate cancer therapies (PCT) on patients’ and partners’ sexual health, their relationships, and about biopsychosocial rehabilitation in prostate cancer (PC) survivorship. Methods: The guidelines panel included international expert researchers and clinicians, and a guideline methodologist. A systematic review of the literature, using the Ovid MEDLINE, Scopus, CINAHL, PsychINFO, LGBT Life, and Embase databases was conducted (1995–2022) according to the Cochrane Handbook for Systematic Reviews of Interventions. Study selection was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Each statement was assigned an evidence strength (A-C) and a recommendation level (strong, moderate, conditional) based on benefit/risk assessment. Data synthesis included meta-analyses of studies deemed of sufficient quality (3), using A Measurement Tool to Assess Systematic Reviews (AMSTAR). Outcomes: Guidelines for sexual health care for patients with prostate cancer were developed, based on available evidence and the expertise of the international panel. Results: The guidelines account for patients’ cultural, ethnic, and racial diversity. They attend to the unique needs of individuals with diverse sexual orientations and gender identities. The guidelines are based on literature review, a theoretical model of sexual recovery after PCT, and 6 principles that promote clinician-initiated discussion of realistic expectations of sexual outcomes and mitigation of sexual side-effects through biopsychosocial rehabilitation. Forty-seven statements address the psychosexual, relationship, and functional domains in addition to statements on lifestyle modification, assessment, provider education, and systemic challenges to providing sexual health care in PC survivorship. Clinical Implications: The guidelines provide clinicians with a comprehensive approach to sexual health care for patients with prostate cancer. Strengths & Limitations: The strength of the study is the comprehensive evaluation of existing evidence on sexual dysfunction and rehabilitation in prostate cancer that can, along with available expert knowledge, best undergird clinical practice. Limitation is the variation in the evidence supporting interventions and the lack of research on issues facing patients with prostate cancer in low and middle-income countries. Conclusion: The guidelines document the distressing sexual sequelae of PCT, provide evidence-based recommendations for sexual rehabilitation and outline areas for future research. Wittmann D, Mehta A, McCaughan E, et al. Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel. J Sex Med 2022;19:1655–1669.
KW - Biopsychosocial
KW - International
KW - Prostate cancer
KW - Sexual rehabilitation
UR - http://www.scopus.com/inward/record.url?scp=85139349911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139349911&partnerID=8YFLogxK
U2 - 10.1016/j.jsxm.2022.08.197
DO - 10.1016/j.jsxm.2022.08.197
M3 - Review article
C2 - 36192299
AN - SCOPUS:85139349911
SN - 1743-6095
VL - 19
SP - 1655
EP - 1669
JO - Journal of Sexual Medicine
JF - Journal of Sexual Medicine
IS - 11
ER -
